Crescita Therapeutics Inc.
CTX.TOTSXHealthcare● Active
$0.79
+$0.00(+0.00%)
Market Cap$14705011
P/E Ratio—
52W High$0.79
52W Low$0.4
Crescita Therapeutics Inc. (CTX.TO) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CTX.TO · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.09M) | ($2.75M) | ($1.99M) | $0.86M | ($1.10M) |
| Depreciation & Amort. | $1.50M | $1.37M | $1.51M | $1.47M | $1.38M |
| Stock-Based Comp. | $0.00M | $0.18M | $0.08M | $0.22M | $0.27M |
| Change in Working Capital | $0.18M | $3.91M | $1.81M | ($3.71M) | ($1.47M) |
| Net Cash from Operations | $1.07M | $2.73M | $2.08M | ($1.02M) | ($1.60M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.33M) | ($1.19M) | ($0.13M) | ($0.23M) | ($0.35M) |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | ($0.97M) | ($2.02M) | ($0.13M) | ($0.29M) | ($0.85M) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.22M) | ($0.32M) | ($0.39M) | ($0.43M) | ($0.10M) |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | ($0.52M) | ($0.44M) | ($0.41M) | ($1.37M) | ($0.35M) |
| Net Cash from Financing | ($0.79M) | ($0.86M) | ($0.78M) | ($1.85M) | ($0.50M) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.74M | $1.54M | $1.94M | ($1.25M) | ($1.94M) |
| FCF Margin %(computed) | 3.50% | 7.87% | 11.09% | -5.31% | -11.59% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · CAD · M
Explore more Crescita Therapeutics Inc. data
About Crescita Therapeutics Inc. (CTX.TO) Cash Flow Statement
Crescita Therapeutics Inc. generated operating cash flow of $0.00B and free cash flow of $0.00B for 2025 — a FCF margin of 3.50%. Capital expenditure was ($0.00B).
Frequently asked questions
CTX.TO · 4 questionsCrescita Therapeutics Inc. generated free cash flow of $0.00B for 2025, down 51.9% year-over-year.
CTX.TO free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10